BRAINSTORM CELL THERAPEUTICS INC. short interest in 2024
In 2024, BRAINSTORM CELL THERAPEUTICS INC.'s disclosed short interest ran from 4.87% of shares outstanding on 12 Jan 2024 to 32.77% on 30 Sep 2024, a change of +27.90 percentage points. The year's high was 32.77% on 30 Sep 2024 and its low 1.30% on 14 Jun 2024, averaging 3.99% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.08 days on 13 Sep 2024. Full history: BRAINSTORM CELL THERAPEUTICS INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
2024 in figures
- Start of year
- 4.87% (12 Jan 2024)
- End of year
- 32.77% (30 Sep 2024)
- Change
- +27.90 pp
- High
- 32.77% (30 Sep 2024)
- Low
- 1.30% (14 Jun 2024)
- Average
- 3.99%
- Highest days to cover
- 6.08 (13 Sep 2024)
- SEC filings marked
- 7
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 4.87% | 2.21 | |
| 31 Jan 2024 | 4.15% | 2.56 | |
| 15 Feb 2024 | 2.52% | 1.55 | |
| 29 Feb 2024 | 2.18% | 1.33 | |
| 15 Mar 2024 | 1.74% | 1.64 | |
| 28 Mar 2024 | 1.97% | 1.00 | |
| 15 Apr 2024 | 2.91% | 1.44 | 10-K filed, results (8-K) |
| 30 Apr 2024 | 3.07% | 3.68 | |
| 15 May 2024 | 2.07% | 1.76 | 10-Q filed |
| 31 May 2024 | 1.64% | 2.25 | |
| 14 Jun 2024 | 1.30% | 1.12 | |
| 28 Jun 2024 | 2.15% | 2.05 | |
| 15 Jul 2024 | 1.58% | 2.03 | |
| 31 Jul 2024 | 1.56% | 2.94 | |
| 15 Aug 2024 | 2.03% | 2.40 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 1.61% | 4.42 | |
| 13 Sep 2024 | 1.75% | 6.08 | |
| 30 Sep 2024 | 32.77% | 4.82 |
See also: BRAINSTORM CELL THERAPEUTICS INC.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.